Analytical Data
-
Gene name
IL-36 gamma
- Application
-
Alternative Names
IL-1F9; IL36g; IL-1H1; IL-1RP2; IL1E; IL1H1; IL1RP2; Interleukin 36, Gamma; Interleukin-1 Homolog 1; Interleukin-1 epsilon; Interleukin 1-Related Protein 2
-
Species
Rat
-
Source
E. coli
-
Tag
N-His
-
Purity
> 90% as determined by SDS-PAGE.
-
Uniprot
F7FNC4
-
Expression Region
Tyr5~Gly153
-
Molecular Weight
20kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IL-36 gamma, also known as interleukin-36 gamma, is a cytokine belonging to the IL-1 family and plays a critical role in the immune response, particularly in the context of inflammatory diseases and skin conditions. This protein has garnered significant interest due to its involvement in modulating both innate and adaptive immune responses. Research indicates that IL-36 gamma is highly expressed in inflammatory conditions such as psoriasis, where it contributes to the proliferation of keratinocytes and the activation of immune cells. The cytokine has been linked to the pathogenesis of various autoimmune diseases, making it a potential target for therapeutic interventions. In recent years, recombinant IL-36 gamma proteins have been developed for research purposes, allowing scientists to investigate their biological functions and therapeutic potential. These studies aim to elucidate the mechanisms by which IL-36 gamma influences inflammation and identify possible pathways for intervention in disease processes. By better understanding this cytokine's role, researchers hope to develop novel treatments that could alleviate symptoms in conditions driven by excessive inflammation, thereby improving patient outcomes. Therefore, exploring IL-36 gamma through recombinant protein studies is crucial for advancing our knowledge of immune regulation and developing targeted therapies for inflammatory diseases.
